Hepatic resection for disseminated germ cell carcinoma

Robert J. Goulet, Jerry M. Hardacre, Lawrence Einhorn, Patrick Loehrer, Jeffrey A. Jones, John P. Donohue, James A. Madura, Jay L. Grosfeld

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Improvements in operative technique and perioperative management have expanded the application of hepatic resection for metastatic cancer. Although a policy of aggressive surgical resection of residual pulmonary and retroperitoneal disease following chemotherapy and normalization of serum tumor markers has been adopted for disseminated germ cell carcinoma, resection of residual hepatic disease in these cases has not been addressed. This report concerns a series of prospectively randomized patients who received systemic cisplatin-based chemotherapy for testis cancer during the past 13 years. Twenty-eight patients underwent resection of residual hepatic disease after serologic remission. Most (23 of 28 patients) of these procedures were preformed concomitantly with other cytoreductive procedures. There were no operative deaths, although 28% of the patients developed complications. The 2-year survival rate was 54%, with an average follow-up of 34 months. Patients were stratified into three groups based on the most aggressive histology noted in the resected specimen. Survival is predicted by this histologic classification system. Hepatic resection can be performed safely and is an important component in the treatment of disseminated testicular carcinoma.

Original languageEnglish
Pages (from-to)290-293
Number of pages4
JournalAnnals of Surgery
Volume212
Issue number3
StatePublished - Sep 1990

Fingerprint

Germ Cells
Carcinoma
Liver
Drug Therapy
Testicular Neoplasms
Tumor Biomarkers
Cisplatin
Lung Diseases
Histology
Survival Rate
Biomarkers
Survival
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Goulet, R. J., Hardacre, J. M., Einhorn, L., Loehrer, P., Jones, J. A., Donohue, J. P., ... Grosfeld, J. L. (1990). Hepatic resection for disseminated germ cell carcinoma. Annals of Surgery, 212(3), 290-293.

Hepatic resection for disseminated germ cell carcinoma. / Goulet, Robert J.; Hardacre, Jerry M.; Einhorn, Lawrence; Loehrer, Patrick; Jones, Jeffrey A.; Donohue, John P.; Madura, James A.; Grosfeld, Jay L.

In: Annals of Surgery, Vol. 212, No. 3, 09.1990, p. 290-293.

Research output: Contribution to journalArticle

Goulet, RJ, Hardacre, JM, Einhorn, L, Loehrer, P, Jones, JA, Donohue, JP, Madura, JA & Grosfeld, JL 1990, 'Hepatic resection for disseminated germ cell carcinoma', Annals of Surgery, vol. 212, no. 3, pp. 290-293.
Goulet RJ, Hardacre JM, Einhorn L, Loehrer P, Jones JA, Donohue JP et al. Hepatic resection for disseminated germ cell carcinoma. Annals of Surgery. 1990 Sep;212(3):290-293.
Goulet, Robert J. ; Hardacre, Jerry M. ; Einhorn, Lawrence ; Loehrer, Patrick ; Jones, Jeffrey A. ; Donohue, John P. ; Madura, James A. ; Grosfeld, Jay L. / Hepatic resection for disseminated germ cell carcinoma. In: Annals of Surgery. 1990 ; Vol. 212, No. 3. pp. 290-293.
@article{27e8dcfc4a7345d285a4652c362226f8,
title = "Hepatic resection for disseminated germ cell carcinoma",
abstract = "Improvements in operative technique and perioperative management have expanded the application of hepatic resection for metastatic cancer. Although a policy of aggressive surgical resection of residual pulmonary and retroperitoneal disease following chemotherapy and normalization of serum tumor markers has been adopted for disseminated germ cell carcinoma, resection of residual hepatic disease in these cases has not been addressed. This report concerns a series of prospectively randomized patients who received systemic cisplatin-based chemotherapy for testis cancer during the past 13 years. Twenty-eight patients underwent resection of residual hepatic disease after serologic remission. Most (23 of 28 patients) of these procedures were preformed concomitantly with other cytoreductive procedures. There were no operative deaths, although 28{\%} of the patients developed complications. The 2-year survival rate was 54{\%}, with an average follow-up of 34 months. Patients were stratified into three groups based on the most aggressive histology noted in the resected specimen. Survival is predicted by this histologic classification system. Hepatic resection can be performed safely and is an important component in the treatment of disseminated testicular carcinoma.",
author = "Goulet, {Robert J.} and Hardacre, {Jerry M.} and Lawrence Einhorn and Patrick Loehrer and Jones, {Jeffrey A.} and Donohue, {John P.} and Madura, {James A.} and Grosfeld, {Jay L.}",
year = "1990",
month = "9",
language = "English",
volume = "212",
pages = "290--293",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Hepatic resection for disseminated germ cell carcinoma

AU - Goulet, Robert J.

AU - Hardacre, Jerry M.

AU - Einhorn, Lawrence

AU - Loehrer, Patrick

AU - Jones, Jeffrey A.

AU - Donohue, John P.

AU - Madura, James A.

AU - Grosfeld, Jay L.

PY - 1990/9

Y1 - 1990/9

N2 - Improvements in operative technique and perioperative management have expanded the application of hepatic resection for metastatic cancer. Although a policy of aggressive surgical resection of residual pulmonary and retroperitoneal disease following chemotherapy and normalization of serum tumor markers has been adopted for disseminated germ cell carcinoma, resection of residual hepatic disease in these cases has not been addressed. This report concerns a series of prospectively randomized patients who received systemic cisplatin-based chemotherapy for testis cancer during the past 13 years. Twenty-eight patients underwent resection of residual hepatic disease after serologic remission. Most (23 of 28 patients) of these procedures were preformed concomitantly with other cytoreductive procedures. There were no operative deaths, although 28% of the patients developed complications. The 2-year survival rate was 54%, with an average follow-up of 34 months. Patients were stratified into three groups based on the most aggressive histology noted in the resected specimen. Survival is predicted by this histologic classification system. Hepatic resection can be performed safely and is an important component in the treatment of disseminated testicular carcinoma.

AB - Improvements in operative technique and perioperative management have expanded the application of hepatic resection for metastatic cancer. Although a policy of aggressive surgical resection of residual pulmonary and retroperitoneal disease following chemotherapy and normalization of serum tumor markers has been adopted for disseminated germ cell carcinoma, resection of residual hepatic disease in these cases has not been addressed. This report concerns a series of prospectively randomized patients who received systemic cisplatin-based chemotherapy for testis cancer during the past 13 years. Twenty-eight patients underwent resection of residual hepatic disease after serologic remission. Most (23 of 28 patients) of these procedures were preformed concomitantly with other cytoreductive procedures. There were no operative deaths, although 28% of the patients developed complications. The 2-year survival rate was 54%, with an average follow-up of 34 months. Patients were stratified into three groups based on the most aggressive histology noted in the resected specimen. Survival is predicted by this histologic classification system. Hepatic resection can be performed safely and is an important component in the treatment of disseminated testicular carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0025081950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025081950&partnerID=8YFLogxK

M3 - Article

VL - 212

SP - 290

EP - 293

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 3

ER -